Horizon's new CEO arrives amid update on takeover bid by Abcam

9 May 2018
terry_pizzie_large

Horizon Discovery’s (LSE: HZD) announcement on the identity of its new chief executive on Tuesday has been followed on Wednesday by a major drop in the share price of the gene editing company.

But the two are not linked, with the reason for Horizon’s stock value plummeting more likely the result of a separate announcement made by Abcam (AIM: ABC), another UK life science research tool specialist.

In mid-April, Abcam made a proposal to acquire Horizon at £1.81 a share, valuing the target firm’s worth at around £270 million ($368 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology